Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results Feb 28, 2013 AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation Feb 26, 2013 Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets Feb 13, 2013 Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) Feb 05, 2013 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 04, 2013 AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation Nov 12, 2012 Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol Nov 12, 2012 Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer Nov 07, 2012 Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets Nov 06, 2012 Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience Oct 15, 2012 Pagination First page « first Previous page ‹ previous … Page 28 Page 29 Page 30 Page 31 Current page 32 Page 33 Page 34 Page 35 Page 36 … Next page next › Last page last »